These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27876532)

  • 1. Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review.
    Dal Prá KJ; Lemos CA; Okamoto R; Soubhia AM; Pellizzer EP
    Int J Oral Maxillofac Surg; 2017 Feb; 46(2):151-156. PubMed ID: 27876532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the utility of serum C-telopeptide cross-link of type 1 collagen as a predictor of bisphosphonate-related osteonecrosis of the jaw: A systematic review and meta-analysis.
    Enciso R; Keaton J; Saleh N; Ahmadieh A; Clark GT; Sedghizadeh PP
    J Am Dent Assoc; 2016 Jul; 147(7):551-560.e11. PubMed ID: 27040417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qualitative and quantitative analysis of the CTX in relation to the period of intake of bisphosphonates: A systematic review.
    Milani M; Manenti RJ; Marcattili D; Marino R; Lomurno AP
    J Biol Regul Homeost Agents; 2021; 35(3 Suppl. 1):219-227. PubMed ID: 34289682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A role for C-terminal cross-linking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery?
    O'Connell JE; Ikeagwani O; Kearns GJ
    Ir J Med Sci; 2012 Jun; 181(2):237-42. PubMed ID: 22223192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers.
    Fleisher KE; Welch G; Kottal S; Craig RG; Saxena D; Glickman RS
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):509-16. PubMed ID: 20674404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-terminal cross-linking telopeptide as a serologic marker for bisphosphonate-related osteonecrosis of the jaw: review of 2 cases.
    Pasoff M
    J Can Dent Assoc; 2013; 79():d51. PubMed ID: 23920073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental investigation of relationship between trauma and bisphosphonate-related osteonecrosis.
    Agaçayak KS; Yuksel H; Atilgan S; Koparal M; Uçan MC; Ozgöz M; Yaman F; Atalay Y; Acikan I
    Niger J Clin Pract; 2014; 17(5):559-64. PubMed ID: 25244263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.
    Lazarovici TS; Mesilaty-Gross S; Vered I; Pariente C; Kanety H; Givol N; Yahalom R; Taicher S; Yarom N
    J Oral Maxillofac Surg; 2010 Sep; 68(9):2241-7. PubMed ID: 20728033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AAOM clinical practice statement: Subject: The use of serum C-terminal telopeptide cross-link of type 1 collagen (CTX) testing in predicting risk of osteonecrosis of the jaw (ONJ).
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2017 Oct; 124(4):367-368. PubMed ID: 30084362
    [No Abstract]   [Full Text] [Related]  

  • 10. Predictive value of the bone markers osteocalcin and C-terminal telopeptide for jaw osteonecrosis in high-risk prostate cancer patients on bisphosphonate therapy: A prospective study.
    Delaka A; Mourmouras N; Zervou-Valvi F; Stravodimos K; Anastasiou I; Delakas D
    Arch Esp Urol; 2019 Nov; 72(9):948-954. PubMed ID: 31697256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
    Kunchur R; Need A; Hughes T; Goss A
    J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis.
    Awad ME; Sun C; Jernigan J; Elsalanty M
    J Am Dent Assoc; 2019 Aug; 150(8):664-675.e8. PubMed ID: 31256803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
    Marx RE; Cillo JE; Ulloa JJ
    J Oral Maxillofac Surg; 2007 Dec; 65(12):2397-410. PubMed ID: 18022461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of serum biomarkers IL-17 and CTX for BRONJ: a pilot clinical case-control study.
    Lee PB; Kiss AS; Nguyen AL; Shi S; Sedghizadeh PP; Le Anh D
    J Calif Dent Assoc; 2013 Nov; 41(11):819-23. PubMed ID: 24341133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: a prospective single-center controlled study.
    Hutcheson A; Cheng A; Kunchar R; Stein B; Sambrook P; Goss A
    J Oral Maxillofac Surg; 2014 Aug; 72(8):1456-62. PubMed ID: 24793621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High C-Terminal Cross-Linking Telopeptide Levels Are Associated With a Minimal Risk of Osteonecrosis of the Jaws in Patients Taking Oral Bisphosphonates and Having Exodontia.
    Friedlander AH; Chang TI; Hazboun RC; Garrett NR
    J Oral Maxillofac Surg; 2015 Sep; 73(9):1735-40. PubMed ID: 25863230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review.
    Fliefel R; Tröltzsch M; Kühnisch J; Ehrenfeld M; Otto S
    Int J Oral Maxillofac Surg; 2015 May; 44(5):568-85. PubMed ID: 25726090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy.
    Thumbigere-Math V; Michalowicz BS; Hughes PJ; Basi DL; Tsai ML; Swenson KK; Rockwell L; Gopalakrishnan R
    J Oral Maxillofac Surg; 2016 Apr; 74(4):738-46. PubMed ID: 26501428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dental extraction as a risk factor for bisphosphonate related osteonecrosis of the jaw in cancer patients: an update.
    Utreja A; Almas K; Javed F
    Odontostomatol Trop; 2013 Jun; 36(142):38-46. PubMed ID: 24073539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?
    Otto S; Tröltzsch M; Jambrovic V; Panya S; Probst F; Ristow O; Ehrenfeld M; Pautke C
    J Craniomaxillofac Surg; 2015 Jul; 43(6):847-54. PubMed ID: 25958767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.